Barbara Klughammer

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

Federico Cappuzzo, Tudor–Eliade Ciuleanu, Lilia Stelmakh et al. · The Lancet Oncology · 2010 · 1.2K citations · Full text

Placebo-controlled Phase 3, Maintenance Treatment, Medicine +7

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

Martin J. van den Bent, Alba A. Brandes, R. Rampling et al. · Journal of Clinical Oncology · 2009 · 561 citations · Full text

Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Tony Mok, Yi‐Long Wu, Jin Soo Lee et al. · Clinical Cancer Research · 2015 · 468 citations

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

Tudor–Eliade Ciuleanu, Lilia Stelmakh, Saulius Cicėnas et al. · The Lancet Oncology · 2012 · 371 citations

Second-line Treatment, Oncology, Cancer Management +6

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Alexander Röth, J Nishimura, Zsolt Nagy et al. · Blood · 2020 · 122 citations · Full text